Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion

Patent metadata

Field	Value
Publication number	US-2016279097-A1
Application number	US-201415029384-A
Country	US
Kind code	A1
Filing date	Oct 15, 2014
Priority date	Oct 15, 2013
Publication date	Sep 29, 2016
Grant date	—

Abstract

The present invention relates to a composition comprising urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, for the stimulation of insulin secretion, and to the use of a compound chosen among urolithin A, urolithin B, urolithin C, urolithin D, or a combination thereof, intended for the stimulation of insulin secretion. The present invention also relates to a composition comprising an effective amount of urolithin B, urolithin C, urolithin D, or a combination thereof, for the treatment or the prevention of diabetes mellitus, and in particular for the treatment or the prevention of type 2 diabetes, and to the use of a compound chosen among urolithin B, urolithin C, urolithin D, and a combination thereof, intended for the treatment or the prevention of diabetes mellitus, and in particular of type 2 diabetes.

First claim

1 . Composition comprising at least one urolithin chosen in the group consisting of: urolithin A, urolithin B, urolithin C, urolithin D and a combination thereof, intended for its use for the stimulation of insulin secretion.

2 . Composition comprising at least one urolithin chosen in the group consisting of: urolithin B, urolithin C, urolithin D and a combination thereof, intended for its use for the treatment or prevention of diabetes mellitus.

3 . Composition according to claim 2 , wherein diabetes mellitus is type 2 diabetes.

4 . Composition according to claim 1 or claim 2 , wherein said urolithin is urolithin B.

5 . Composition according to claim 1 or claim 2 , wherein said urolithin is urolithin C.

6 . Composition according to claim 1 or claim 2 , wherein said urolithin is urolithin D.

7 . Composition according to claim 2 , comprising urolithin A and at least one urolithin chosen in the group consisting of: urolithin B, urolithin C, urolithin D and a combination thereof.

8 . Composition according to claim 1 or claim 2 , wherein the treated patient is chosen among: a prediabetic patient, a patient whose fasting glycemia is comprised between 1 and 1.25 g·L −1 and a patient whose post-prandial glycemia is comprised between 1.40 and 1.99 g·L −1

9 . Composition according to claim 1 or claim 2 , wherein the treated patient is chosen among: a diabetic patient, a patient whose fasting glycemia is equal or superior to 1.26 g·L −1 and a patient whose post-prandial glycemia is equal or superior to 2 g·L −1 .

10 . Composition according to claim 1 or claim 2 , for its use as a drug, as a food product or as a nutritional supplement.

11 . Composition according to claim 1 comprising:
a) at least one urolithin chosen in the group consisting of: urolithin A, urolithin B, urolithin C, urolithin D and a combination thereof, and
b) a compound able to stimulate insulin secretion, intended for its use for the stimulation of insulin secretion.

12 . Composition according to claim 11 wherein said compound able to stimulate insulin secretion is chosen in the group consisting of:
sulfonylureas, GLP-1 analogs and DPP4 inhibitors.

13 . Composition according to claim 11 comprising urolithin C and glibenclamide.

14 . Composition according to claim 11 comprising urolithin C and exendin.

15 . Composition according to claim 2 comprising:
a) at least one urolithin chosen in the group consisting of: urolithin B, urolithin C, urolithin D and a combination thereof, and
b) a compound able to stimulate insulin secretion, intended for its use for the treatment or prevention of type 2 diabetes.

16 . Composition according to claim 15 , wherein said compound able to stimulate insulin secretion is chosen in the group consisting of:
sulfonylureas, GLP-1 analogs and DPP4 inhibitors.

17 . Composition according to claim 15 comprising urolithin C and glibenclamide.

18 . Composition according to claim 15 comprising urolithin C and exendin.

19 . Composition according to claim 1 or claim 2 , wherein said composition is a food product, a nutritional supplement or a pharmaceutical composition.

20 . A method for stimulating insulin secretion comprising administering to a mammal in need thereof a compound chosen in the group consisting of: urolithin A, urolithin B, urolithin C, urolithin D and a combination thereof.

21 . A method for stimulating insulin secretion comprising administering to a mammal in need thereof a food product or nutritional supplement comprising a compound chosen in the group consisting of: urolithin A, urolithin B, urolithin C, urolithin D and a combination thereof.

22 . A method for stimulating insulin secretion comprising administering to a mammal in need thereof urolithin C, alone or in combination with at least one urolithin chosen in the group consisting of urolithin A, urolithin B and urolithin D.

23 . A method for stimulating insulin secretion comprising administering to a mammal in need thereof urolithin D, alone or in combination with at least one urolithin chosen in the group consisting of urolithin A, urolithin B and urolithin C.

24 . The method according to claim 20 , further comprising a compound able to stimulate insulin secretion.

25 . The Method according to claim 24 , wherein said compound able to stimulate insulin secretion is chosen in the group consisting of: sulfonylureas, GLP-1 analogs and DPP4 inhibitors.

26 . The Method according to claim 24 , wherein urolithin C is in combination with glibenclamide.

27 . The Method according to claim 26 , wherein urolithin C is in combination with exenatide.

28 . Composition according to claim 1 or claim 2 comprising as a combination product for a simultaneous, separate or sequential use, an effective amount of a compound able to stimulate insulin secretion.

29 . Pharmaceutical composition comprising an effective amount of at least one urolithin chosen in the group consisting of: urolithin A, urolithin B, urolithin C, urolithin D and a combination thereof, and a pharmaceutically acceptable vehicle.

Assignees

• Centre Nat De La Rech Scient (Cnrs)
• Univ Montpellier
• Univ Of Parma
• Ecole Nat Superieure De Chimie
• Centre Nat Rech Scient
• Ecole Nat Superieure De Chimie

Inventors

• Cros Gerard
• Crozier Alan
• Dall'Asta Margherita
• Del Rio Daniele
• Magous Richard
• Oiry Catherine

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title

• A61K31/37 Primary

  Coumarins, e.g. psoralen · CPC title

• A61K31/255

  of sulfoxy acids or sulfur analogues thereof · CPC title

• A61K38/26

  Glucagons · CPC title